

A. National Historic Landmarks (NHL) Program

NHL Program matters will be considered, during which the Board may consider the following:

Nominations for NHL Designation

Commonwealth of the Northern Mariana Islands.

- LATTE QUARRY AT AS NIEVES, Rota, CNMI.

District of Columbia

- THE FURIES COLLECTIVE, Washington, DC.

Kentucky

- BIG BONE LICK SITE, Union, KY.

Nebraska

- KREGEL WINDMILL COMPANY FACTORY, Nebraska City, NE.

South Carolina

- CHARLESTON CIGAR FACTORY, Charleston, SC.

Proposed Amendments to Existing NHL Designations

Alaska

- SITKA NAVAL OPERATING BASE AND U.S. ARMY COASTAL DEFENSES (updated documentation), Sitka, AK.
- LADD FIELD (updated documentation), Fairbanks, AK.

Hawai'i

- PU'UKOHOLĀ HEIAU (updated documentation, boundary change), Kawaihae, HI.

Michigan

- QUINCY MINING COMPANY HISTORIC DISTRICT (updated documentation, boundary change), Houghton County, MI.
- CALUMET HISTORIC DISTRICT (updated documentation, boundary change), Calumet, MI.

Missouri

- WATKINS MILL (updated documentation), Lawson, MO.

Texas

- FORT BROWN (updated documentation, boundary change), Brownsville, TX.

Virginia

- CEDAR CREEK BATTLEFIELD AND BELLE GROVE (updated documentation, boundary change), Middletown, VA.

Wyoming

- WYOMING STATE CAPITOL BUILDING AND GROUNDS (updated documentation), Cheyenne, WY.

Proposed Withdrawal of Existing Designations

North Carolina

- JOSEPHUS DANIELS HOUSE (WAKESTONE), Raleigh, NC.

South Carolina

- USS CLAMAGORE (former), Mount Pleasant, SC.

B. National Natural Landmarks (NNL) Program

NNL Program matters will be considered, during which the Board may consider the following:

Nomination for NNL Designation

Texas

- INDEPENDENCE CREEK PRESERVE, Terrell County, TX.

Interested persons may choose to make oral comments at the meeting during the designated time for this purpose. Depending on the number of people wishing to comment and the time available, the amount of time for oral comments may be limited. Interested parties should contact Monique VanLandingham (see **FOR FURTHER INFORMATION CONTACT**) for advance placement on the public speaker list for this meeting. Members of the public may also choose to submit written comments by emailing them to monique_vanlandingham@partner.nps.gov. Due to time constraints during the meeting, the Board is not able to read written public comments submitted into the record. All comments will be made part of the public record and will be electronically distributed to all Board members. Detailed minutes of the meeting will be available for public inspection within 90 days of the meeting.

Meeting Accessibility/Special Accommodations: Please make requests in advance for sign language interpreter services, assistive listening devices, or other reasonable accommodations. We ask that you contact the person listed in the **FOR FURTHER INFORMATION CONTACT** section of this notice at least seven (7) business days prior to the meeting to give the Department of the Interior sufficient time to process your request. All reasonable accommodation requests are managed on a case-by-case basis.

Public Disclosure of Comments: Before including your address, phone number, email address, or other personal identifying information in your comment, you should be aware that your entire comment—including your personal identifying information—may be made publicly available at any time. While you can ask us in your comment to withhold your personal identifying

information from public review, we cannot guarantee that we will be able to do so.

Authority: 5 U.S.C. Ch. 10.

Alma Ripps,

Chief, Office of Policy.

[FR Doc. 2024-03755 Filed 2-22-24; 8:45 am]

BILLING CODE 4312-52-P

DEPARTMENT OF JUSTICE**Drug Enforcement Administration**

[Docket No. DEA-1322]

Bulk Manufacturer of Controlled Substances Application: Siemens Healthcare Diagnostics Inc.

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

SUMMARY: Siemens Healthcare Diagnostics Inc. has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to **SUPPLEMENTARY INFORMATION** listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before April 23, 2024. Such persons may also file a written request for a hearing on the application on or before April 23, 2024.

ADDRESSES: The Drug Enforcement Administration (DEA) requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to <https://www.regulations.gov> and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on <https://www.regulations.gov>. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this is notice that on January 10, 2024, Siemens Healthcare Diagnostics Inc., 100 GBC Drive, Mailstop 108, Newark, Delaware 19702-2461 applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

| Controlled substance | Drug code | Schedule |
|----------------------|-----------|----------|
| Ecgonine | 9180 | II |

The company plans to produce the listed controlled substance in bulk to be used in the manufacture of the DEA exempt products. No other activities for this drug code is authorized for this registration.

Marsha Ikner,

Acting Deputy Assistant Administrator.

[FR Doc. 2024-03712 Filed 2-22-24; 8:45 am]

BILLING CODE P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-1323]

Importer of Controlled Substances Application: Meridian Medical Technologies, LLC

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

SUMMARY: Meridian Medical Technologies, LLC has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to **SUPPLEMENTARY INFORMATION** listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before March 25, 2024. Such persons may also file a written request for a hearing on the application on or before March 25, 2024.

ADDRESSES: The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to <https://www.regulations.gov> and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on <https://www.regulations.gov>. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment. All requests for a hearing must be sent to: (1) Drug Enforcement Administration,

Attn: Hearing Clerk/OALJ, 8701 Morrisette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrisette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this is notice that on January 17, 2024, Meridian Medical Technologies, LLC, 2555 Hermelin Drive, Saint Louis, Missouri 63144, applied to be registered as an importer of the following basic class(es) of controlled substance(s):

| Controlled substance | Drug code | Schedule |
|----------------------|-----------|----------|
| Morphine | 9300 | II |

The company plans to import the listed controlled substances for analytical purposes only. No other activities for these drug codes are authorized for this registration.

Approval of permit applications will occur only when the registrant's business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale.

Marsha Ikner,

Acting Deputy Assistant Administrator.

[FR Doc. 2024-03714 Filed 2-22-24; 8:45 am]

BILLING CODE P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-1318]

Importer of Controlled Substances Application: Pall Life Sciences PR, LLC

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

SUMMARY: Pall Life Sciences PR, LLC has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to **SUPPLEMENTARY INFORMATION** listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before March 25, 2024. Such

persons may also file a written request for a hearing on the application on or before March 25, 2024.

ADDRESSES: The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to <https://www.regulations.gov> and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on <https://www.regulations.gov>. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment. All requests for a hearing must be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrisette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrisette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this is notice that on January 11, 2024, Pall Life Sciences PR, LLC, Road 194, Kilometer 0.4, Fajardo, Puerto Rico 00738, applied to be registered as an importer of the following basic class(es) of controlled substance(s):

| Controlled substance | Drug code | Schedule |
|----------------------|-----------|----------|
| Morphine | 9300 | II |

The company plans to import the listed controlled substances for research purposes, drug testing, and analysis to support foreign regulatory compliance of finished dosage forms to foreign markets. No other activities for these drug codes are authorized for this registration.

Approval of permit applications will occur only when the registrant's business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or non-